Given that palmitoylation is crucial for RAS carcinogenic activation and palmitic acid rescued the repressive effects of CLDN6 on BC cell, we hypothesized that CLDN6 might hinder BC malignant progression by manipulating RAS palmitoylation. The gene discussed is CLDN6; the disease is breast cancer.